Gyon Technologies Capital Management, LP Protagonist Therapeutics, Inc Transaction History

Gyon Technologies Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$23.34 - $36.08 $440,705 - $681,262	-18,882 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$17.63 - $37.1 $285,147 - $600,055	-16,174 Reduced 46.14%	18,882 $646,000
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $896,381 - $1.57 Million	35,056 New	35,056 $1.57 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $1.42 Million - $2.33 Million	-74,652 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $1.38 Million - $1.88 Million	74,652 New	74,652 $1.51 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.